From bench to bedside, 2-in-1 design expedites phase 2/3 oncology drug development

Frontiers in Oncology

Oncology

Cong Chen¹  Xuekui Zhang² 

[1] Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States;Department of Mathematics and Statistics, University of Victoria, Victoria, BC, Canada;

关键词: Project FrontRunner;    adaptive design;    one-trial approach;    accelerated approval;    two-trial approach;   

DOI  :  10.3389/fonc.2023.1251672

 received in 2023-07-02, accepted in 2023-09-25,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Chen and Zhang